STAPHYLOCOCCUS AUREUS VACCINE COMPOSITIONS

The present disclosure relates to immunogenic compositions for inducing an immune response in a subject for the treatment and/or prevention of a Staphylococcus aureus infection. The immunogenic compositions disclosed herein comprise a S. aureus protein A (SpA) polypeptide and a S. aureus Leukocidin...

Full description

Saved in:
Bibliographic Details
Main Authors SOMANI, SANDEEP, GEURTSEN, JEROEN, MORROW, BRIAN, BUCKLEY, PETER T, POOLMAN, JAN THEUNIS, KONSTANTINOV, SERGEY, LUO, JINQUAN, TORRES, VICTOR J
Format Patent
LanguageEnglish
French
Published 06.10.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present disclosure relates to immunogenic compositions for inducing an immune response in a subject for the treatment and/or prevention of a Staphylococcus aureus infection. The immunogenic compositions disclosed herein comprise a S. aureus protein A (SpA) polypeptide and a S. aureus Leukocidin A (LukA) and/or Leukocidin B (LukB) variant polypeptide. The present disclosure further relates to methods of generating an immune response against S. aureus in a subject that involve administering the disclosed immunogenic compositions. La présente divulgation concerne des compositions immunogènes permettant d'induire une réponse immunitaire chez un sujet pour le traitement et/ou la prévention d'une infection à Staphylococcus aureus. Les compositions immunogènes de la divulgation comprennent un polypeptide de protéine A de S. aureus (SpA) et un polypeptide variant leucocidine A (LukA) et/ou leucocidine B (LukB) de S. aureus. La présente divulgation concerne en outre des méthodes de génération d'une réponse immunitaire contre S. aureus chez un sujet qui impliquent l'administration des compositions immunogènes divulguées.
Bibliography:Application Number: CA20223215751